Recent events
Recent events tied to this brand in public sources.
Back to profile95 entries · Page 2 of 5
2021
AstraZeneca and VaxEquity enter RNA therapeutics research collaboration
AstraZeneca entered a long-term research collaboration with VaxEquity to discover, develop and commercialise a self-amplifying RNA therapeutics platform. The collaboration includes investment and research funding, and AstraZeneca may partner with VaxEquity on up to 26 drug targets.
2021
VaxEquity announces strategic collaboration with AstraZeneca
VaxEquity announced a strategic research collaboration with AstraZeneca to optimise and validate VaxEquity’s self-amplifying RNA platform and advance therapeutic programmes. AstraZeneca will provide research and development funding, has an option to collaborate on up to 26 drug targets, and made an upfront equity investment in VaxEquity.
2021
RedHill and Aurobindo settle Movantik patent litigation
RedHill Biopharma, AstraZeneca and Nektar Therapeutics entered into a settlement and license agreement with Aurobindo Pharma USA, resolving their U.S. patent litigation over a proposed generic version of Movantik. The agreement allows Aurobindo to sell a generic version no earlier than April 1, 2031, subject to FDA approval and specified circumstances.
2021
PUMA Biotechnology and Wyeth sue AstraZeneca over Tagrisso patent
PUMA Biotechnology Inc. and Wyeth LLC filed a lawsuit against AstraZeneca Pharmaceuticals in Delaware, alleging that AstraZeneca’s Tagrisso infringes their patent. The allegations are claims in the lawsuit, not a court determination.
2021
Zipline begins distributing UK-donated AstraZeneca vaccines in Ghana
Zipline announced the start of drone deliveries of a new shipment of UK-donated AstraZeneca COVID-19 vaccines to selected health facilities from four distribution centers across Ghana.
2021
AstraZeneca and European Commission reach vaccine delivery settlement
AstraZeneca and the European Commission reached a settlement covering delivery of 200 million pending COVID-19 vaccine doses, with AstraZeneca committing to staged deliveries through the first quarter of 2022.
2021
AstraZeneca completes acquisition of Alexion
AstraZeneca completed its $39 billion acquisition of Alexion Pharmaceuticals, following regulatory clearances. The deal included cash and newly issued AstraZeneca shares for Alexion shareholders.
2021
RedHill and partners settle Movantik patent litigation with Apotex
RedHill Biopharma announced that RedHill Biopharma Inc., AstraZeneca entities and Nektar Therapeutics had entered into a settlement and license agreement with Apotex entities, resolving their U.S. patent litigation over Apotex's application to market a generic version of Movantik. Under the agreement, Apotex may not sell a generic version in the U.S. until October 1, 2030, subject to FDA approval or earlier circumstances specified in the agreement.
2021
AstraZeneca appoints Susan Galbraith to lead oncology R&D
AstraZeneca announced Susan Galbraith's appointment as executive vice president of oncology research and development. In the role, she will lead oncology R&D from initial discovery through late-stage development.
2021
AstraZeneca opens a flagship store on JD Health
AstraZeneca opened its self-operated flagship store on JD Health, expanding the companies' online health-service cooperation.
2021
AstraZeneca sues Alembic over ticagrelor patent
AstraZeneca filed a lawsuit against Alembic Pharmaceuticals, alleging that Alembic's generic ticagrelor product would infringe AstraZeneca's patent. The article reports the allegation and does not establish a court determination.
2021
AstraZeneca South Africa announces sponsorship of BrandMed health centres
AstraZeneca South Africa announced that it would sponsor BrandMed to establish fifteen BrandMed Syntro-P Health Centres of Excellence.
2021
AstraZeneca sues Glaxo over Zejula licensing agreement
AstraZeneca filed a lawsuit in the U.K. against GlaxoSmithKline, alleging that a 2012 licensing agreement over the Zejula cancer drug was breached and seeking a greater share of sales.
2021
Sun Pharma acquires Oxra trademark and manufacturing rights in India
Sun Pharma acquired the Indian rights to the Oxra, Oxramet and Oxraduo trademarks from AstraZeneca AB, and took a patent license from AstraZeneca AB to manufacture and commercialize dapagliflozin and its combination with metformin in India.
2021
Sun Pharma acquires Indian trademark rights for dapagliflozin products
Sun Pharma acquired the Indian rights to the Oxra, Oxramet and Oxraduo trademarks from AstraZeneca AB, with effect from 28 May 2021.
2021
Sun Pharma and AstraZeneca India discontinue distribution agreement
Sun Pharma and AstraZeneca India discontinued their 2016 distribution agreement, effective May 28, 2021.
2021
AstraZeneca AB licenses dapagliflozin rights to Sun Pharma in India
AstraZeneca AB granted Sun Pharma a patent license to manufacture and commercialize dapagliflozin and its combination with metformin in India, effective 28 May 2021.
2021
EU sues AstraZeneca over vaccine supply contract
The European Commission sued AstraZeneca, arguing that the company had not met its obligations under the COVID-19 vaccine supply contract and lacked an appropriate plan for timely deliveries.
2021
AstraZeneca responds to EU legal action
AstraZeneca said it regretted the EU's legal action, said it believed the proceedings had no legal basis, and said it would defend itself in court.
2021
EU initiates legal proceedings against AstraZeneca over vaccine deliveries
The European Union initiated legal proceedings against AstraZeneca, alleging that the company had not respected terms of its vaccine supply contract and lacked a reliable strategy to ensure timely deliveries. AstraZeneca said it had fully complied with the deal and would defend itself in court.